Synlogic Inc SYBX
Trading Information
- Previous Close Price
- $1.06
- Day Range
- $1.05–1.05
- 52-Week Range
- $0.56–1.87
- Bid/Ask
- $1.02 / $1.08
- Shares Outstanding
- 12.25M
- Market Cap
- $12.28M
- Volume/Avg
- 990 / 65,377
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
- Website
- https://www.synlogictx.com
Valuation
|
Metric
|
SYBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.03 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SYBX
Financial Strength
|
Metric
|
SYBX
|
|---|---|
Quick Ratio | 9.02 |
Current Ratio | 9.19 |
Interest Coverage | — |
Quick Ratio
SYBX
Profitability
|
Metric
|
SYBX
|
|---|---|
Return on Assets (Normalized) | −20.57% |
Return on Equity (Normalized) | −26.84% |
Return on Invested Capital (Normalized) | −31.68% |
Return on Assets
SYBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|P&#!!< | LOCK|H!%V | $123B | |||
| Moderna Inc
MRNA
| LOCK|MdJ>h&@ | LOCK|rMt | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|C@$%DB | LOCK|>t!v@ | $78B | |||
| argenx SE ADR
ARGX
| LOCK|@%$%&Mf | LOCK|?# | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GzS&jf& | LOCK|#&< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|LrL<Bnm | LOCK|J@TG! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Bxf%qwH | LOCK|tBk& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&Z?V$t^ | LOCK|g?N | $22B | |||
| Incyte Corp
INCY
| LOCK|^%%$HgJ | LOCK|M@^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%Tx<vrQ | LOCK|&f& | $14B |
United States